– Dr. Dias is a biotechnology and pharmaceutical industry executive with more than 20 years of global experience launching oncology products –
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced that Rosh Dias, MD, MRCP, has been appointed Chief Medical Officer. Dr. Dias will be a member of the company’s management team and will oversee a number of clinical functions, including medical affairs, clinical operations, pharmacovigilance and clinical development.
“Rosh is a terrific addition to Coherus at a time when we are highly focused on successful new product launches and advancing our immuno-oncology development pipeline,” said Denny Lanfear, CEO of Coherus. “A seasoned pharmaceutical executive with a proven track record of success leading medical affairs across multiple therapeutic areas, including oncology, he brings significant experience and expertise as we prepare for the launch of up to four new products. over the next 18 months.
“I am delighted to join Coherus at this pivotal moment when the Company is preparing for the launch of several new products in immuno-oncology, immunology and ophthalmology,” said Dr. Dias. “With toripalimab and its clinical and preclinical pipeline of combined PD-1 candidates, Coherus is well positioned to become a leader in the development and commercialization of innovative drugs in immuno-oncology. I am very excited about Coherus’ work to advance these new treatments and the possibilities of impacting and helping cancer patients across multiple tumor types. »
Dr. Dias brings more than 20 years of pharmaceutical and biotechnology industry experience leading US and global teams in clinical development and medical affairs across multiple disease areas, including oncology, cardiometabolic health, and rare diseases. Dr. Dias recently joined Coherus from Spruce Biosciences, Inc., where he was Medical Director overseeing global clinical development and strategy. Prior to Spruce, he served as Medical Director at Indivior PLC, a global commercial pharmaceutical company focused on addiction and other serious mental disorders. From 2014 to 2018, Dr. Dias held leadership positions at Amgen, Inc., most recently as Vice President, Global Scientific Affairs, and at Amgen’s subsidiary, Onxy Pharmaceuticals, Inc., as head of global medical and scientific affairs. Prior to Onyx, Dr. Dias worked for 10 years at Novartis Oncology in roles of increasing responsibility, including leadership roles in the global organization, United States and Australia, where he led clinical development efforts and medical affairs with an emphasis on oncology, hematology and rare diseases.
Dr Dias holds an MD from Charing Cross and Westminster Medical School in the UK, and is a Fellow of the Royal College of Physicians with a postgraduate degree in Internal Medicine.
About Coherus BioSciences
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies for the treatment of cancer. Coherus’ strategy is to build a leading immuno-oncology franchise funded by cash generated from net sales of its diversified portfolio of FDA-approved therapeutic products.
In 2021, Coherus obtained a license for toripalimab, an anti-PD-1 antibody, in the United States and Canada. A BLA for toripalimab for the treatment of metastatic or recurrent nasopharyngeal carcinoma is currently undergoing priority review by the FDA, with a target action date of April 30, 2022. Toripalimab is also being evaluated in clinical trials pivots for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus and bladder.
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta® in the United States and plans to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the United States in 2023. The FDA is currently reviewing the BLA for CIMERLITM, formerly known as CHS-201, a biosimilar of Lucentis® (ranibizumab), with a target action date of August 2022. Coherus is also developing CHS-305, a biosimilar of Avastin® (bevacizumab).
Except for historical information contained in this press release, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including including, but not limited to, statements regarding Coherus’ ability to grow its immuno-oncology franchise; ability of Coherus to generate cash; Coherus investment projects; Coherus’ expectations regarding its ability to launch products in the near term; and Coherus’ expectations regarding its ability to become a leader in the development and commercialization of immuno-oncology drugs.
These forward-looking statements involve substantial risks and uncertainties that could cause the actual results, performance or achievements of Coherus to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to the COVID-19 pandemic; risks relating to our existing and potential collaboration partners; the risks of the drug development position of Coherus’ competitors; risks and uncertainties of the regulatory approval process, including the timeliness of regulatory review and the timing of Coherus’ regulatory filings; the risk of FDA review issues; the risk of execution by Coherus of its change of strategy from a focus on biosimilars to a strategy using cash from biosimilars to fund an immuno-oncology franchise; the risk that Coherus may not be able to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of potential litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus assumes no obligation to update or revise any forward-looking statements. For a more detailed description of the material risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business generally, see Coherus’ Annual Report on Form 10- K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on February 23, 2022, including the section entitled “Risk Factors”, and in other documents it files with the Securities and Exchange Commission.
Coherus BioSciences, Inc.
Source: Coherus BioSciences, Inc.